Sundrug Co (9989) AI Stock Analysis

Compare

0 Followers

JP:9989 Dividends

Top Page

Sundrug Co

(OTC:9989)

78Outperform

Sundrug Co's strong financial performance, characterized by solid revenue growth and efficient cost management, is the key driver of the stock's score. The technical analysis supports a positive outlook due to upward price trends, despite missing some indicators. Valuation remains moderate, with an attractive dividend yield enhancing appeal. The company is well-positioned in the pharmaceuticals industry, though optimizing expense management and capital allocation could bolster long-term growth prospects.

Sundrug Co (9989) vs. S&P 500 (SPY)

Market Cap

$549.07B

Dividend Yield2.67%

Average Volume (3M)427.37K

Price to Earnings (P/E)18.2

Beta (1Y)0.43

Revenue Growth7.13%

EPS Growth7.29%

CountryJP

Employees6,662

SectorHealthcare

Sector Strength56

IndustryMedical - Pharmaceuticals

Share Statistics

EPS (TTM)257.99

Shares Outstanding119,331,184

10 Day Avg. Volume330,670

30 Day Avg. Volume427,370

Financial Highlights & Ratios

PEG Ratio2.50

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$4,949.98

Price Target Upside5.41% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Sundrug Co Business Overview & Revenue Model

Company DescriptionSundrug Co (9989) is a leading Japanese company operating in the retail and pharmacy sectors. It primarily focuses on the sale of pharmaceuticals, cosmetics, and health-related products through a widespread network of drugstores and pharmacies across Japan. The company is recognized for its commitment to offering a diverse range of high-quality products that cater to the health and wellness needs of its customers.

How the Company Makes MoneySundrug Co generates revenue primarily through its extensive network of retail outlets, which sell pharmaceuticals, cosmetics, and health-related products. The company's key revenue streams include the sale of prescription and over-the-counter medications, personal care items, and beauty products. Additionally, Sundrug Co benefits from its private-label products, which offer higher margins. The company may also engage in strategic partnerships with pharmaceutical companies and suppliers to enhance its product offerings and supply chain efficiency, further contributing to its earnings.

Sundrug Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Breakdown
Income Statement		Total Revenue
751.78B	690.46B	648.73B	634.31B	617.77B
	Gross Profit
189.32B	171.95B	156.51B	158.55B	154.62B
	EBIT
41.00B	37.45B	34.05B	37.34B	36.60B
	EBITDA
56.53B	49.52B	44.26B	46.01B	44.97B
	Net Income Common Stockholders
29.13B	25.70B	23.85B	25.33B	23.69B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
69.70B	80.87B	89.33B	86.50B	80.70B
	Total Assets
420.21B	360.67B	325.77B	308.53B	284.28B
	Total Debt
35.00B	939.00M	529.00M	114.00M	154.00M
	Net Debt
-34.70B	-79.93B	-88.80B	-86.38B	-80.55B
	Total Liabilities
167.12B	124.34B	105.18B	103.37B	97.45B
	Stockholders Equity
253.09B	236.33B	220.59B	205.16B	186.82B
Cash Flow		Free Cash Flow
2.96B	11.27B	11.89B	15.29B	20.97B
	Operating Cash Flow
41.19B	37.38B	31.68B	31.76B	32.27B
	Investing Cash Flow
-74.85B	-28.51B	-20.66B	-17.90B	-13.95B
	Financing Cash Flow
22.49B	-17.33B	-8.19B	-8.06B	-7.86B

Sundrug Co Technical Analysis

Technical Analysis Sentiment

Positive

Last Price4696.00

Price Trends

50DMA

4322.90

Positive

100DMA

4150.43

Positive

200DMA

4018.45

Positive

Market Momentum

MACD

127.83

Positive

RSI

61.51

Neutral

STOCH

78.47

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9989, the sentiment is Positive. The current price of 4696 is above the 20-day moving average (MA) of 4564.20, above the 50-day MA of 4322.90, and above the 200-day MA of 4018.45, indicating a bullish trend. The MACD of 127.83 indicates Positive momentum. The RSI at 61.51 is Neutral, neither overbought nor oversold. The STOCH value of 78.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9989.

Sundrug Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9989	78 Outperform	$549.07B	18.20	11.63%	2.67%	7.13%	7.29%
7643	77 Outperform	¥15.99B	11.75		3.43%	9.00%	8.06%
7649	74 Outperform	¥567.69B	21.22	10.45%	1.10%	17.94%	18.31%
3141	74 Outperform	¥525.82B	34.91		1.43%	5.56%	-43.53%
3148	67 Neutral	¥196.29B	14.12		2.29%	8.98%	0.10%
Sector *	52 Neutral	$5.36B	3.81	-42.57%	2.86%	17.10%	1.33%

* Healthcare Sector Average

Performance Comparison

JP:9989

Sundrug Co

4,696.00

350.05

8.05%

JP:3141

Welcia Holdings Co., Ltd.

2,521.50

241.44

10.59%

JP:3148

Create SD Holdings Co., Ltd.

3,105.00

-236.34

-7.07%

JP:7643

Daiichi Co., Ltd.

1,399.00

146.20

11.67%

JP:7649

Sugi Holdings Co

3,012.00

643.22

27.15%

Sundrug Co Corporate Events

SUNDRUG CO., LTD. Announces Simplified Merger with Wholly Owned Subsidiary

Feb 14, 2025

SUNDRUG CO., LTD. has announced its decision to execute an absorption-type merger with its wholly owned subsidiary, SUNDRUG Saketen LLC, which is engaged in the alcoholic beverages retailing business. This strategic move aims to expand the company’s alcoholic beverage retail operations and improve management efficiency. As this is a merger with a wholly owned subsidiary, the company states that the impact on its consolidated financial results will be minimal.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.